Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After

Status Completed

Clinical Trial Summary

Larynx preservation remains a very challenging approach in patients with larynx/pharynx cancer. A first attempt consisted of induction chemotherapy followed in good responders by irradiation. This approach allowed to preserve 60 % of the larynx without any significant difference in survival. The second attempt consisted of concurrent chemo-irradiation. This approach provided a higher larynx preservation rate but survival remained unchanged and mucosal toxicity was also higher. A third approach is currently under evaluation: induction chemotherapy followed by concurrent chemo-irradiation in good responders.

Clinical Trial Description

At ASCO 2004 there were 3 major presentations issuing an increasing in survival:

- the update of the MACH-NC meta-analysis showed that actually only concurrent chemo-irradiation trials found a significantly improved survival (in particular the addition of cisplatinum alone to radiotherapy)

- the addition of docetaxel to the cisplatinum-5FU regimen (TPF) when compared with cisplatinum--5FU (PF)

- the addition of cetuximab to irradiation

On this basis we decided to carry-out a randomized phase II for previously untreated patients requiring a total laryngectomy:

All patients after a complete work-up including a CTscan will receive 3 cycles of TPF(T: 75 mg/m², P: 75 mg/m² and 5FU 750 mg/m²).

Patients with response over 50 % (endoscopy and CTscan) will be randomized to receive either irradiation (70 Gy) and cisplatinum (100 mg/m² on D1, D22 and D43) or irradiation (70 Gy) with cetuximab (loading dose of 400 mg followed by weekly 250 mg for a total of 8 cycles.

Patients with less than 50% decease in tumour volume after TPF, patients with residual or recurrent disease after either RT-CDDP or RT-cetuximab will get salvage total laryngectomy. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00169247
Study type	Interventional
Source	Groupe Oncologie Radiotherapie Tete et Cou
Contact
Status	Completed
Phase	Phase 2
Start date	October 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06016699` - Immunological Function After Radiation With Either Proton or Photon Therapy
Completed	`NCT03292341` - Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients.	N/A
Completed	`NCT03653039` - Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy	N/A
Completed	`NCT05746780` - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Recruiting	`NCT05793151` - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy	N/A
Completed	`NCT01700647` - Breath Testing in Early and Late Larynx Cancer	N/A
Completed	`NCT00600223` - Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches	N/A
Recruiting	`NCT03759431` - Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer	Phase 2
Active, not recruiting	`NCT02586207` - Pembrolizumab in Combination With CRT for LA-SCCHN	Phase 1
Recruiting	`NCT04057209` - VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer	N/A
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT06086119` - Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
Suspended	`NCT04368702` - CONFIRM: Magnetic Resonance Guided Radiation Therapy	N/A
Completed	`NCT05217147` - An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma
Active, not recruiting	`NCT03082534` - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma	Phase 2
Completed	`NCT00158652` - Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC	Phase 3
Terminated	`NCT03479463` - Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy
Completed	`NCT03096808` - Adaptive Radiotherapy for Head and Neck Cancer	Phase 2
Completed	`NCT03028766` - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer	Phase 1
Completed	`NCT00359645` - Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms